TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03729180

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Routine Elective Surgery- In patient or out patient elective surgery
Description: Participants will be undergoing routine planned surgeries.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Routine Elective Surgery- In patient or out patient elective surgery
Description: Participants will be undergoing routine planned surgeries.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Routine Elective Surgery- In patient or out patient elective surgery
Description: Participants will be undergoing routine planned surgeries.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood test for genetic testing
Description: Blood test to determine differences in genes which may affect how certain medications affect the participant. All patients will consent to collection of a blood sample for preemptive genotyping across a panel of actionable germline variants predicting drug response or toxicity risk.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood test for genetic testing
Description: Blood test to determine differences in genes which may affect how certain medications affect the participant. All patients will consent to collection of a blood sample for preemptive genotyping across a panel of actionable germline variants predicting drug response or toxicity risk.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood test for genetic testing
Description: Blood test to determine differences in genes which may affect how certain medications affect the participant. All patients will consent to collection of a blood sample for preemptive genotyping across a panel of actionable germline variants predicting drug response or toxicity risk.

Intervention type: OTHER
Group type: OTHER
Intervention: Drug-genetic Profile
Description: Profile describing drugs that may be high-risk, those that should be used with caution, or drugs that are favorable to use based on the participants genes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drug-genetic Profile
Description: Profile describing drugs that may be high-risk, those that should be used with caution, or drugs that are favorable to use based on the participants genes.
Study: NCT03340350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Minocycline capsule
Study: NCT03754933

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad/PNP
Description: Ad/PNP is a replication defective adenoviral vector expressing E. coli Purine Nucleoside Phosphorylase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Fludarabine phosphate is an anticancer agent currently used to treatment patients with chronic lymphocytic leukemia.
Study: NCT03311126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine is a chemotherapeutic agent that has dual functional properties of both an alkylating agent and a nitrogen mustard. Through these unique cytostatic properties, bendamustine is able to inhibit DNA transcription, replication, and repair. Bendamustine is approved in the U.S. for treatment of chronic lymphocytic leukemia (CLL) and for indolent B cell non-Hodgkin lymphomas (NHLs) progressing during or within 6 months of rituximab or a rituximab - containing regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab is a glycoengineered, humanized, type II anti-CD20 monoclonal antibody (mAb).
Study: NCT04140487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT00374556

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3mg placebo capsule, once daily at bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone
Description: 3mg capsule, once daily at bedtime
Study: NCT04146688

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music Balance Board
Description: The SSM is measured with an innovative tool (Music Balance Board) developed at the University of Ghent (Belgium) and specially designed to record the movements of the elderly in a natural and comfortable position This chair is equipped with a tablet and sensors that record the movements of the hand and body during the SSM to a musical sequence. The analysis will focus on the difference between the participant's striking and the beat of the music measured using this chair.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music Balance Board
Description: The SSM is measured with an innovative tool (Music Balance Board) developed at the University of Ghent (Belgium) and specially designed to record the movements of the elderly in a natural and comfortable position This chair is equipped with a tablet and sensors that record the movements of the hand and body during the SSM to a musical sequence. The analysis will focus on the difference between the participant's striking and the beat of the music measured using this chair.
Study: NCT04426630

Intervention type: OTHER
Group type: OTHER
Intervention: mHealth for heart failure patients in Uganda
Description: Patients at Uganda Heart Institute will be enrolled in an mHealth program intended to promote self-care for heart failure and improve their healthcare quality of life.
Study: NCT04049279

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BiMobile standard cement
Description: BiMobile dual mobility cup, in a standard size after optimal reaming, resulting in a cement mantle of approximately 2mm.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BiMobile larger cement
Description: BiMobile dual mobility cup, in one size smaller than standard after optimal reaming, resulting in a cement mantle of approximately 4mm.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Avantage standard cement
Description: Avantage dual mobility cup, in a standard size after optimal reaming, resulting in a cement mantle of approximately 2mm.
Study: NCT02502929

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Services

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Plus Medication Therapy Management
Study: NCT02427165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPL554
Description: A dual PDE3 and PDE4 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPL554
Description: A dual PDE3 and PDE4 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPL554
Description: A dual PDE3 and PDE4 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPL554
Description: A dual PDE3 and PDE4 inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol
Description: a beta-2 receptor agonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol
Description: a beta-2 receptor agonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: RPL554 placebo containing no active ingredients
Study: NCT02579603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Nintedanib 150mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Nintedanib 150mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Study: NCT01929252

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: 2mcg.kg-1 dexmedetomidine wound infiltration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: 0.25% levobupivacaine (40ml) wound infiltration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: 0.25% levobupivacaine (40ml) wound infiltration
Study: NCT04036084

Intervention type: DIAGNOSTIC_TEST
Intervention: Cerebral Magnetic resonance imaging (MRI)
Description: Cerebral Magnetic resonance imaging (MRI) 3 Tesla at Inclusion Cerebral Magnetic resonance imaging (MRI) 3 Tesla at Month 1 Cerebral Magnetic resonance imaging (MRI) 3 Tesla at Year 1

Intervention type: DIAGNOSTIC_TEST
Intervention: Cerebral Magnetic resonance imaging (MRI)
Description: Cerebral Magnetic resonance imaging (MRI) 3 Tesla at Inclusion Cerebral Magnetic resonance imaging (MRI) 3 Tesla at Month 1 Cerebral Magnetic resonance imaging (MRI) 3 Tesla at Year 1
Study: NCT00768222

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: silk suture
Description: skin closure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VICRYL* Plus suture
Description: skin closure
Study: NCT00278629

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hematopoietic stem cell transplantation
Description: Autologous hematopoietic stem cell transplantation
Study: NCT00203567

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carbamazepine ER
Description: Active study drug, no comparator
Study: NCT02462161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Description: Participants will administer 20 IU insulin aspart two times per day with an intranasal delivery device.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will administer placebo two times per day with an intranasal delivery device.
Study: NCT00312013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nadroparin
Description: Patients will received all standard anti-cancer treatments. Therapeutic doses of nadroparin will be administered, subcutaneous for 2 weeks followed by half therapeutic doses for 4 weeks. After 4 weeks of wash-out, subsequent 2 week periods of therapeutic doses will be given for a total of 6 cycles each separated by a 4 week wash out. The study treatment period ends at week 46 regardless of the number of cycles achieved.
Study: NCT02265328

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bovine colostrum
Description: Oral Bovine colostrum 200 ml (20 gram) TDS × 2 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enteral Nutrition
Description: Enteral nutrition: Protein 1.5 gm/kg/day, energy (kcal) 40/kg/day, carbohydrate 67-80%, Fat 20-33%.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: prednisolone
Description: Oral prednisolone 40mg/day × 4 weeks and tapered to \<40mg/day for next 4 weeks. (If Lilli score \> 0.45 after 7 days, then prednisolone would be stopped)
Study: NCT04294888

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: rTMS is a method to focally and reversibly stimulate a pre-specified cortical target. rTMS works through the principle of electromagnetic induction.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: rTMS is a method to focally and reversibly stimulate a pre-specified cortical target. rTMS works through the principle of electromagnetic induction.
Study: NCT02094235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6005 0.05%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 g placebo ointment
Study: NCT00762151

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Negative Control (Regular Toothpaste)
Description: Regular Toothpaste

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Positive Control (anti-plaque/anti-bacterial toothpaste)
Description: Standard anti-plaque and anti-bacterial toothpaste

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prototype (AN0128 Toothpaste)
Description: AN0128 Toothpaste
Study: NCT03560362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine liposome

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine / Epinephrine
Study: NCT03874234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3186899
Description: GSK3186899 will be available as white to slightly colored, spray dried powder in a bottle to be administered orally along with mixture of propylene glycol and water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3186899
Description: GSK3186899 will be available as white to slightly colored, spray dried powder in a bottle to be administered orally along with mixture of propylene glycol and water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3186899
Description: GSK3186899 will be available as white to slightly colored, spray dried powder in a bottle to be administered orally along with mixture of propylene glycol and water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3186899
Description: GSK3186899 will be available as white to slightly colored, spray dried powder in a bottle to be administered orally along with mixture of propylene glycol and water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be available as white to slightly colored, blend powder in a bottle to be administered orally along with mixture of propylene glycol and water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be available as white to slightly colored, blend powder in a bottle to be administered orally along with mixture of propylene glycol and water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be available as white to slightly colored, blend powder in a bottle to be administered orally along with mixture of propylene glycol and water.
Study: NCT01819935

Intervention type: DRUG
Intervention: linezolid (Zyvox)
Description: As prescribed-this is retrospective cohort of existing clinical data.

Intervention type: DRUG
Intervention: vancomycin
Description: As prescribed-this is retrospective cohort of existing clinical data.
Study: NCT02303587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Study: NCT02094235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6005 0.2%
Study: NCT01193985

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TIGR Matrix Surgical Mesh
Description: Lichtenstein repair of inguinal hernia using TIGR Matrix Surgical Mesh
Study: NCT04094389

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orthotic continuous wear group
Description: Performed exclusively for research purposes, participants will be assigned at entrance to the study to either wear the orthotic continuously, only during waking hours, or only while sleeping. There will be three participants in each of the three groups.~Participants in the continuous wear group will be instructed to wear their orthotic continuously around the clock as tolerated with removal for hygiene and home exercise program (HEP) performance. Consistent with standard of care for the treatment of trigger finger with an orthotic, all nine of the participants will be instructed to wear their orthotic for at least six weeks, as tolerated, with continuation of orthotic wear up to 10 weeks if their triggering has not completely abated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orthotic wear during waking hours only group
Description: Performed exclusively for research purposes, participants will be assigned at entrance to the study to either wear the orthotic continuously, only during waking hours, or only while sleeping. There will be three participants in each of the three groups.~Participants in the waking hours only group will be instructed to wear their orthotic during all waking hours as tolerated, with removal for hygiene, HEP performance, but not at night while sleeping. Consistent with standard of care for the treatment of trigger finger with an orthotic, all nine of the participants will be instructed to wear their orthotic for at least six weeks, as tolerated, with continuation of orthotic wear up to 10 weeks if their triggering has not completely abated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orthotic wear only while sleeping group
Description: Performed exclusively for research purposes, participants will be assigned at entrance to the study to either wear the orthotic continuously, only during waking hours, or only while sleeping. There will be three participants in each of the three groups.~In the night-wear group, participants will be told to wear their orthosis only at night. Consistent with standard of care for the treatment of trigger finger with an orthotic, all nine of the participants will be instructed to wear their orthotic for at least six weeks, as tolerated, with continuation of orthotic wear up to 10 weeks if their triggering has not completely abated
Study: NCT03316560

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV2tYF-GRK1-RPGR
Description: Adeno-associated virus vector expressing a human RPGR gene
Study: NCT03618550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal doxorubicin
Description: 15mg/m\^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal doxorubicin
Description: 15mg/m\^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles
Study: NCT02895373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprostadil
Description: 5ng/kg/min, continuously, start within 24h of initiation of ECMO therapy and end at the end of ECMO therapy
Study: NCT02895373

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride solution
Description: continuously, start within 24h of initiation of ECMO therapy and end at the end of ECMO therapy
Study: NCT00204373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole (Prevacid)
Description: Lansoprazole 30mg capsules. dose is individualized to each subject based on gastric acid production. The range is 30 mg to 450 mg daily.
Study: NCT02822235

Intervention type: OTHER
Intervention: No Intervention

Intervention type: OTHER
Intervention: No Intervention
Study: NCT01414153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4.0 mg iSONEP
Description: 4.0 mg iSONEP given monthly intravitreously for 4 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4.0 mg iSONEP
Description: 4.0 mg iSONEP given monthly intravitreously for 4 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5 mg iSONEP
Description: 0.5 mg iSONEP given monthly intravitreously for 4 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea
Description: 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea given monthly intravitreously for 4 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea
Description: 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea given monthly intravitreously for 4 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea
Description: 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea given monthly intravitreously for 4 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sham injection
Description: administered monthly for 4 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sham injection
Description: administered monthly for 4 months
Study: NCT02096185

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3 dimensional tomosynthesis imaging
Description: Each operative specimen will be imaged twice using each condition

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 2 dimensional digital imaging
Study: NCT03503318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV-46000
Description: TV-46000 will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV-46000
Description: TV-46000 will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to TV-46000 will be administered per schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching to TV-46000 will be administered per schedule specified in the arm.
Study: NCT02576938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone (Optional)
Description: Administered topically

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Triamcinolone (Optional)
Description: Administered topically
Study: NCT04535388

Intervention type: DEVICE
Group type: OTHER
Intervention: LK scleral lens
Description: LK scleral lens fitting and application were done for 12 weeks.
Study: NCT02297763

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: quetiapine
Description: patient body weight \<50kg : quetiapine 12.5mg patient body weight \>=50kg : quetiapine 25mg~quetiapine 12.5mg (bwt \<50kg ) or 25mg (bwt\>= 50kg) study medicine is pulverized to power and melted in 10cc tepid water. The study medicine(quetiapine) will be provided as liquid form.~The study medicine(quetiapine) was provided as liquid form (medicine was pulverized and melted in 10cc water).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The placebo is made of 100mg of corn starch which is melted in 10cc water.